Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Mr. McNally has a history of getting products to the marketplace first, then getting the company sold at maximum value.
pmontx, 2018 it pretty close now!
You say $5 now but more later... Are there any specific upcoming milestones that will drive your target price higher? News of successful procedures coming out of the two new training centers, for example? Or specific published milestones being achieved?
Here's the list from the Short Form Prospectus, below. My personal take is that most of these should be fairly easy to achieve given the stated functionality of the device from the Nicholson surgeons. The tedium comes in the documentation for the regulatory filings, but with proper reviews before submission and working with the agencies in advance as they had been doing, risk should be relatively low. With the right QA team in place, I would not be surprised to see a few more milestones announced as completed ahead of schedule.
Quick list of Milestones:
Q3: Complete and verify system design
architecture, including performance testing in
laboratory environment and design of
surgeon simulation training modules
- Implement design changes and retest
system and subsystems
- Update Design History File and
documentation for relevant modules of
Company Quality Management
Systems (“QMS”)
- Complete initial requirements and
architecture for surgeon simulation
software and training program design,
as required in preparation for FDA
submittal
Q4: Verify system performance in pre-clinical
(live animal labs, swine), while establishing
clear regulatory pathways for US and Europe
- Complete and report on pre-clinical
live animal (swine) studies at strategic
facilities in US and Europe
- Confirm FDA and CE Mark pathways
in coordination with regulatory
authorities
Q1 '18: Complete software development, system
design and update Design History File for
regulatory filing applications
Q2 '18: Verify production system operation with
clinical experts under rigorous formal
(summative) human factors evaluation under
simulated robotic manipulation exercises, and
exercise completed surgeon simulation
software and training program
Q3 '18: Complete and document pre-clinical live
animal (swine) surgery studies that are
representative of anticipated human surgeries
for FDA submittal
Q4 '18: Prepare and submit 510(k) application to
FDA and prepare technical file for CE Mark
and submit to European Notified Body
- Publish white papers on pre-clinical
studies containing evidence of system
performance in live animal surgeries
that are representative of anticipated
human surgeries
H1 '19: Anticipated receipt of FDA 510(k) clearance
and CE Mark
Should I track everyone's responses and then do some averaging to see where we stand as a group? Everyone would certainly have the right to vote their own conscience, but we might be more influential as a like-minded group if we have a target in mind and agree to vote accordingly. We would just need to ensure everyone provides their input.
When we were gauging our potential influence as a group of shareholders several months back, there were 188M shares outstanding, and we iHubbers as a group (those who reported in) held around 6% of them. I have increased my position by about 30% since then and I think most people here did as well if they could, plus we seem to have a fair number of new contributors here since then as well. There are more outstanding share now, but it is not unreasonable to think that between our increases in holdings plus the newer contributors, we could be sitting on over 10% of the company. If we band together, we might have more voting influence than Longtai! (They have warrants as well, but I don't think warrants represent voting shares if they aren't exercised... maybe a good reason for warrant holders to exercise sooner rather than later; they can improve their voting power if a buyout offer comes around quickly.)
IITF, I think warrants would still be exercisable for a buyout so I estimated 400M shares; therefore $2B would be $5/share.
If Titan had "build and buy" all over it, we would never be hurting for funding the way we have been on occasion. It does seem to be the perfect company for that acquisition model, but it doesn't seem to be happening, at least not yet.
As for a buyout scenario, we need to start thinking a bit more seriously about what price level we want or need. When adding warrants to outstanding shares, we are looking at somewhere around 400M shares total? If so, a $2B buyout would get us $5/share. Is that sufficient? Certainly compared to today's PPS levels, it sounds outstanding, but does that achieve our individual financial goals regarding this stock? Were we hoping for two to four times that much in the next 5 years or so? Or are we still bitter enough about the company's history that we would take $2 just to be done with the whole thing?
We may want to discuss this a bit here on the board to get a feel for where everyone stands, because if an offer comes around, I assume shareholders get to vote on it. We each need to think about how much we would be willing to accept for a Yes vote on a buyout. I'm closer to $10/share, or $4B before I would jump on it that quickly. We will want to consider timing with regard to milestones and project timelines - how close are we to FDA filing or approval by then? Have there been any hiccups which represent risk, or has it been smooth sailing with the new team so the perception of risk is minimal? For some folks, who the buyer is might affect their decision as well (I'm just gonna be a "Show me the money" guy if it happens; I don't care who is paying as long as they pay enough).
The article pointed out that there is a shortage of good target companies in med tech right now, so one offer could easily be the first of a bidding war, given the impact SPORT is expected to have on the robotic surgery marketplace. Just another thing to keep in mind. We might not want to jump too quickly on the first offer; they need to give other potential buyers time to formulate a competing offer if they want.
Maybe it's premature, or maybe now is a good time to start thinking about this, because when it hits, it will be mostly out of the blue. With the propensity for information to be leaked with this stock (prices always spike just before good news), any time we see a healthy jump for no apparent reason means something is coming, and any time we get the "random" spike, it could be a buyout offer causing it.
I think it might be time to start the dialog amongst ourselves to see where we stand as a group, and maybe be able to leverage our collective voting power to better meet everyone's long term objectives with this investment. I think we are in a good position for some strong bargaining if it is going to happen. And if it doesn't happen, we are still in a great place and moving in the right direction.
Not reverse...3:1 split; stockholders have 3X as many shares at 1/3 the price.
It's funny how a few weeks ago, half a million shares traded would have looked like a huge day, and now it seems like peanuts... I assume lots of people aren't at work due to the holiday; pretty quiet here on the board as well. I'm almost surprised the market isn't closed for Columbus Day/Indigenous People's Day/Displaced Spotted Newt Acknowledgement Day/Capitalist Atonement Day... or whatever fictitious nouveau pseudo-holiday they want to fabricate next in order to hijack another piece of our country's history. But I digress - once again.
At least PPS is moving in the right direction at the moment. My September IRA statements came in and looked really really nice, thanks mostly to our Little Stock That Could. (Chug Chug). The post-split ISRG stock at around $350/share is starting to look more vulnerable now! Go Titan!
I also think that getting systems into the latter two locations will be much quicker and simpler that at Nicholson by virtue of the fact that they now have already done it, plus they know what other prep work needs to happen, and some training materials, fixtures, etc. are already developed by Nicholson. The two subsequent installations should be pretty much a slam dunk. I would not be surprised if folks from those two locations have already been through some training at Nicholson on the SPORT device so they can dive right in when the hardware arrives at their respective site.
I do appreciate the added detail for clarification!
I also recall a couple companies breaking into a new technology 15 years ago... I guess these lawsuits do have precedents, although the end result was staggering success!
http://surgrob.blogspot.com/2010/03/vintage-report-on-intuitive-vs-computer.html
So, what happened to "award-winning IP" at Titan? We went from having the best IP protection around and getting through an intense IP review just a few months ago to "Hey, we'll probably get sued for patent infringement!"
Might I suggest a career in politics for the flip-floppers out there? I'm sticking with Mr. Brar and the "IP is sewn up tight" story.
Those numbers happen to be (maybe coincidence, maybe software glitch) the current Bid (.223) and Ask (.238).
I'm seeing 2500 shares on the bid and 2500 on the ask... These seem to be the quantities market makers like to use; it seems like very often it is 2500 or 5000. Looks like plain old manipulation. Maybe they need to get the price down so their uncle can buy in cheap.
The Caribbean certainly has it's allure... By the time we are ready, they should have everything fixed up again. Vegas also has a little healing to do right now, but they also should be back in better moods when it's party time for us.
I expect an occasional dip as well, whether for profit taking, or in advance of a raise (would be nice to know like so many others seem to know... leaks!) but it shouldn't have to be double-digit drops when it happens. As long as we continue to have more up days then down, or at least bigger climbs on the ups to maintain the positive trend, we will do just fine.
WSJ ideas... Just a few bullet points that may be worth mentioning if you correspond with either of the previously provided email addresses (I'll paste them in below again for convenience).
Playing the "Why aren't you covering this?" card:
- Tell them you are a stockholder or are interested in their stock but don't seem to be getting any information from WSJ.
-You have been reading about recent events from the management change to milestone achievements to training site placements
- Early reviews by the surgeons who used it are rave reviews about this groundbreaking new technology
- Mention some specific benefits, e.g. one incision instead of four or five, better dexterity, surgeon comfort, enhanced 3D visibility, smaller packaging, lower price and costs...
- Let them know you are getting disappointed that they haven't provided any coverage while others are.
Playing the "I heard stuff, can you please provide more info or coverage?" card:
- Your profession can tie into how/why/where you have heard/became aware of Titan
- You have been looking around the web and see glowing reviews from recent events being talked about, maybe specify one or two newsworthy announcements to mention to them
- You are looking for guidance and background on Titan and you typically turn to the WSJ as a trusted source of information for investment choices or technological updates (if you are in medicine)
- You might express some disappointment that you haven't seen anything from them yet about Titan
- Outright ask them if they are aware of Titan Medical and if they plan to provide any coverage of the story as it is unfolding; maybe mention that others are starting to pick up the story.
For either option:
- Feel free to provide your own background. Telling them how your professional career ties in will give your request more credibility.
- If you are a subscriber, point that out as well!
- Put everything in your own words; maybe try to purposefully not use some of my words, lest we look like we are starting some sort of a coordinated campaign to get them on board (we don't want to look like we are begging!)
- Pick a couple/few of the above points as they pertain to you and your interests, and can maybe expound upon them a little more in your email.
Feel free to post your letters here as well, if you wish to share!
Christopher.mims@wsj.com
Science & Tech Columnist - I'll probably write to him because of my technical background
Dennis.Berman@wsj.com
Business including Health Sector - if you are more medical or investment oriented, he might be a better recipient for you.
I'm in! We will need a couple different approaches, some asking why they aren't covering it, and others asking WSJ for info about them (as if we didn't know). I'll start putting together some outlines today if I get a chance.
BTW... who was it, a week or two ago, that said it might be tough to break through a resistance level somewhere around 28 cents??? It sounded great at the time because we were still far enough away, but I'm ready to find the next level!
Part of TRXC's stated strategy was and still is to hire former Intuitive reps. It also was the direction the old Titan management team was going, including Paige something-or-other...
In her nearly two decades of robotic surgery experience, my wife has known some really good reps from ISRG, and a couple that were not so well liked. The early reps were all excellent. She also said that ISRG tends to shuffle the deck fairly often to ensure the reps never get TOO comfortable or cozy with their customer base and territory. The problem is that these reps are human beings with lives and families and friends... not everyone is willing to uproot their family because some benevolent overlord says you must. So not all ex-ISRG reps were canned for poor performance; some are exceptional sales and technical reps who could easily be swayed to get back into the robotics game, and some of them might be even more interested if it gives them a chance to compete with their former overlords!
True, which I believe at least partially answers the Distribution question.
I hope these guys are doing SOMETHING useful... Then again, the Titan web site still shows Mr. Barker's letter from November 8 as "What's new" and they still only list four board members.
The word "Distribution" only appears once in all these descriptions but I don't know of any small companies that have a separate "Distribution" department. It tends to be a coordinated effort between Sales and Production, with Production usually also handling management of inventory and shipping/receiving.
Frederic Nahon, VP Sales EMEA & Asia
Mr. Nahon brings 20 years of successful experience in complex and disruptive sales management in robotic surgery in Europe, Middle East and Africa (EMEA) markets. With his years of successful tenure at Intuitive Surgical and Stereotaxis, he has a proven track record in new market development including building relationships with the scientific community and management of Key Opinion Leaders in diverse surgical disciplinary markets. Mr. Nahon has the capacity to work in dynamic startup environments, to build strong teams and manage a distribution network around EMEA region.
Sachin A. Sankholkar, VP Marketing
Mr. Sankholkar is a 20+ year’s medical device industry veteran. During his 15+ years at Intuitive Surgical, Mr. Sankholkar held a variety of product management roles where he launched 40+ instruments over 3 robotic platforms for several surgical specialties during the vital early years of product adoption. Mr. Sankholkar enjoys an extensive robotic surgeon network with a proven track record of building strong Key Opinion Leaders relationships and facilitating successful adoption of robotic technology to the required standard of care. Mr. Sankholkar earned an MBA from University of Southern California in Los Angeles, CA and holds a Master of Science degree in Biomedical Engineering from Drexel University in Philadelphia, PA.
Chris Seibert, VP Business Development
Mr. Seibert has 12+ years in the medical device industry spanning Clinical Sales, Sales Leadership, Strategic Planning and Product Development at companies ranging from those with a very mature product life cycle to early stage, pre-submission products. Mr. Seibert has an in-depth, national network of innovative physicians and healthcare executives. Mr. Seibert has worked for four start-up companies and has extensive relationships across the IDN/GPO landscape. Mr. Seibert has a Bachelor of Arts from the University of Alabama, a Master of Arts in Human Relations from the University of Oklahoma and an MBA from the University of South Alabama.
A large shareholder coming into play is inherently dilutive; those shares need to come from somewhere. A partner is most likely dilutive as well; they used the term Partnership for Longtai, and their $2M cost us another 18M shares of dilution. Very tough to be a development stage company looking for non-dilutive source of income because everything, even a distribution agreement, is purely speculative. Maybe McNally was able to convince Longtai to convert because Longtai was able to do without that money for over a year by then anyway, and it's possible that Longtai's sole existence is to distribute SPORT in Asia anyway.
I just had the strangest dream... I felt as though an entire weekend transpired and that it was now October. But here we are on Thursday, September 28, reading posts 59673 and 59689 again...
Oh, wait... it IS October and this is just a disturbing case of deja vu? I guess I'll try a different explanation. Ballpark numbers as always, for this hypo-pathetical situation.
Titan is squat next to the monster players right now. Say for example J&J bought Titan. They have a market cap of almost $350B. ISRG is barely over 1% of that. Let's just say J&J bought Titan and handed Titan shareholders J&J stock to buy us out. One J&J share is $130; Titan is around four for a buck. We are looking at an effective 500 to 1 reverse split for our current investment. One share of J&J for every 500 shares of Titan right now. People are bitching about a 30 to one, so why would you want a 500 to 1 RS?
Okay, so now my 350K shares of Titan are 700 shares of J&J. Let's say SPORT rules the market and quickly grows to ISRG's size. Value around $3.5B. We're stuck with J&J stock. All this time and money with Titan, and in 5 years we get a whopping 1% bump from our investment in robotic surgery, because that is what $3.5B is to J&J. I'm not in this for a 1% bump over 5 years. None of us are. Okay, you say a 1:1 share buyout is improbable... is 2 for 1 dollar value a better buyout scenario? It just means we wait around 5 years for a 2% return on our investment in robotic surgery.
Who suffers by getting a partner? Me. And Titan management. And everyone else here on this message board who is in it to win it. We are here for the big score, not to be part of something that adds one percent to J&J's bottom line. Or for Medtronic with their $100B+ market cap, it's 3%. Big deal. Not why I'm here. I don't want them to buy us out now either. I remember when THE PRIOR MANAGEMENT TEAM ran out of money and stopped "production" (actually, development; we still are not in "production").
We are churning 3M to 5M shares per day at nearly triple the share price was had around the time of the last raise. I think it is a safe bet that they can now raise enough funding to keep us rolling. If it means adding outstanding share count (most likely) then so be it. I have a stock that could get me 100X my investment in a few years. I'd rather give up 15 or 20% of that growth (dilution) for funding now instead of giving up 99.9% of that growth because some monster corporation swallows us while we are so cheap. Sure, J&J or Medtronic could easily buy us and add a couple points to their bottom line; that's what those conglomerates do over and over. But that is not why any of us are here. Except apparently for you.
Message in reply to:
OR Nurse
Titan has been having investor conferences for a while now. Why would they not agree to a partner when they are starving for cash? Again, they do not care about their shareholders. Dilution is easier. The shareholders suffer. The bottom line is the product has to come to market. I do not understand why Titan would not have a huge sigh of relief, get a partner, share in the wealth with this partner, and advertise the partnership everywhere they can! Shareholders would go crazy, the pps would skyrocket and ISRG and other developing robotic companies would go "Oh no!" Who suffers by getting a partner? Who suffers knowing we have enough capital to get us to FDA approval? Unless you agree that there is more financial incentive with board members NOT to partner. Which again means more dilution. Not being a Debbie Downer. Just being a realist. Wouldn't it be nice if a partnership was announced, we had enough money and we would not have to comment daily on how much working capital. Remember when we had to stop production because we ran out of money?
I think what Diamond is saying is that in less than a couple years Mazor took a very specialized robotic product product and wound up with a $1.2B market cap. If we get to that level market cap in such a short time, the math looks like (factoring in a little more dilution to get there, I'll say 300M shares total) we'd be at $4/share, or at 400M shares (more dilution factored in) it's still $3/share. But Mazor is highly specialized and therefore a much smaller market. We could see teens or much more in a short period of time.
At least I hope that's what Diamond's message was hinting at!
Message in reply to:
just look at Mazor as a reference.
https://web.tmxmoney.com/quote.php?qm_symbol=MZOR:US
It's an extremely specialized robot for brain surgery basically and the Sport will easily reach a much wider audience.
One more way to look at the future...
About 8 weeks ago we dropped below .10 a share. Closing in on triple that amount today means only 1/3 of the dilution we would have had at those levels. They will need to raise funds at some point, so the higher it goes by then, the less dilution. If we can go another month or more before another raise, dilution could be 1/5 or 1/6 of what it would have been when we were in the basement. To me, that constitutes some really good news!
I made my last two buys at $.11 and the prior one at $.16; those got my DCA under $.47 for all my Titan holdings (350K). I need (want, really... it's a goal) over $10/share to consider retirement. I just need to continue to be patient, which has been a lot easier to do these past couple weeks. If my DCA was $2.00, I would just need to continue to be patient! Not really any different except that I will have SOME profitability sooner than at the $2.00 level. I think everyone should have the same opinion of Titan's current management based on their performance, regardless of when they bought in. And because of where they are in the product development life cycle, everyone just needs to be patient, again regardless of when they bought in. Unless they are shorting the stock, of course.
Small players like Titan (and possibly TRXC if they can pawn off a few more systems) give us small-time investor types the chance to reap pretty substantial rewards in this market space. ISRG is already quite expensive and with competition looming, the long term outlook may not be quite as favorable. And other big players getting into the market likely have more diversity in their product lines which will inherently water down the effect of a booming robotics market on their PPS; in fact their robotics line can possibly cannibalize some of their other surgical product line sales.
We're all in this together! If only a few NFL players felt that way too...
From SEDAR filing, August 2017:
Compensation to the Executive Officers amounted to $405,187 and $756,531 for the three and six months ended June 30,
2017.
This is split somehow 6 ways between Barker, Bernholtz, McNally, Randall, Schellhorn, and Wolfe. That averages about $250K/yr per person; I'm sure it is not evenly distributed among them. If you look at what an average person makes in any of their positions, they are not being overpaid. Two months ago our market cap was around $20M, now it's around $70M and rising quickly. I think they are earning their income, whatever it happens to be for each of them.
I thought I read somewhere before that they hold board meetings approximately monthly, and each attendee is paid $1000 to attend. Sure, most of us working slobs would like to make $1000 in a matter of a couple hours (their transportation, lodging, etc. might actually come out of this stipend) but in reality, that isn't so hard on the shareholders. For those of you in the device industry, think about some of the truly elaborate expenses some of these companies dish out (feel free to provide some examples!) and Titan is somewhere between efficient and miserly by comparison to the average. When real revenue starts flowing, I'm sure budgets will increase tremendously but it will be well justified by then.
They aren't suffering financially, but I suspect most of them are putting in a lot more hours than 40 per week, and likely more hours than you or me (I know, some of you probably work WAY too much!). This isn't some little side project for them; this is a personal challenge that they are obviously taking seriously.
Message in reply to:
Unfortunately, board members are paid handsomely and are not suffering like the poor shareholder.
So, if you need to be clairvoyant to make money with this stock, why is anyone here?
And how does being long in this stock not workout for anyone with patience?
If stockholders are all going to lose, what bring you to this table? Just curious.
$10, I'm retired. Anything less, I'm working at least a couple more years. Please, no buyouts yet because it won't likely be $10 a share! Yet! FDA cleared? It wouldn't be as low as $10 a share!
It's not just the spreading of the word organically, but at some point in the near future a few bigger news and investing outlets HAVE to pick up on this. Are we still bugging WSJ this week? It really should be getting difficult for them to ignore Titan much longer. And when one or two big outlets pick up on it, that's when other news outlets need to jump in too.
I'm also with Belize on warrants; not that they aren't pertinent but I think more so in the background only. With a 5 year window to exercise them, you could buy more shares on the market today, then sell a small portion of those shares in 3-4 years (couple/few bucks a piece) to exercise all your warrants. We need to consider their existence when thinking about outstanding shares, but I don't see them as a substantial source of income for the company for quite a while.
Almost a million shares right out of the gate!! That kind of volume could be considered a really good indicator as well!
Just perusing the SAB list on Titan's site. Dr. Advincula, of course, is at Columbia, but so is Dr. Burke. And Dr. Advincula also used to hold two Director positions at Nicholson. Nice to have a tight network working with us!
If Mrs Brooklyn is asking daily, she knows something is up and probably has already Googled it! If ads for Coach purses and Louboutin shoes are showing up in the side bars of your web pages, that confirms she knows about Titan and has already started shopping for expensive shoes and bags!
My wife has already suggested we raid my Scottrade account (50K shares of TITXF) when it is enough to pay off her 20K student loan (so when it hits $.40/share...). I told her that most likely that would prove to be a half million or maybe even a million dollar mistake in no more than five years. I bought my ISRG shares at $11.65 - could have sold them 6 months later to buy a car, but she's glad we held on to those for years as well. I wish I hadn't bailed out at $750, but I thought if they hadn't split by then, they would NEVER split. Oh well... Used some of that money for more Titan!
http://www.titanmedicalinc.com/titan-medical-partners-with-columbia-university-medical-center-for-sport-feasibility-and-validation-studies/
Columbia it is!!! And it's the announcement to explain the last minute jump yesterday!
(Why did Yahoo have this news before it was even on Titan's site?)
SPORT19? Why not SPORT20 so we could legitimately call you ST?
Message in reply to:
Sure tomorrow before the open and ST thank you for your support!
Okay, I won't mention the other "startup" company who managed to sell a system in Germany about 8 months ago and just celebrated their 100th case... How profitable is a system used on an average of about a dozen cases per month? I think SPORT's ease of use will make it a much more popular and profitable option! Actually, I don't know if da Vinci cases make money for hospitals or just get patients in the door as a marketing tool, even if the cases lose money. Anyone know that answer?
Sorry... earlier post I said ALF-X when I meant SurgiBot...
https://www.medtechy.com/the-ticker/articles/2017/transenterix-is-one-step-closer-to-fda-approval-for-senhance
Here's another one I find interesting... Transenterix expects the purchasing cycle for Senhance to be 12 to 18 months for most hospitals. On the down side, it would probably hold somewhat true for Titan. On the up side, even if TRXC gets Senhance clearance by the end of this year, Titan will probably be cleared as well just about the time Senhance could start seeing any US sales. I wonder how many hospitals will start the procurement approval process for Senhance, only to jump over to SPORT because it is suddenly available for sale? They could inadvertently be laying the groundwork for system sales which get converted to ours... so we don't have to wait 12 months after approval to start taking revenue!
https://www.facebook.com/transenterix
They are providing updates on their device via Facebook, but virtually nothing about Nicholson since they dropped it off. I searched for Senhance and Nicholson and all I got was a bunch of copies of the original announcement, one link to their Facebook page, and one of my old iHub posts after their first Nicholson announcement (57708) which is even more applicable now!
They just hit 100 cases with Senhance in Germany. That took a while, didn't it?
They brag about submitting their AI doc to the FDA on 9/18, ahead of schedule. An AI request means they sent in their 510K submission and it was incomplete or insufficient, but at least it wasn't flat out rejected like their ALF-X submission was. There was a press release on the 18th but it didn't seem to generate a lot of attention. However, if someone wants to dig to see how long an FDA approval typically comes after an AI response, there may be an opportunity for folks to stir up some short term profit when and IF they get their approval! If I had the money, I probably would have already put it into Titan, but... I'm guessing that's why their stock has been sneaking in a generally upward direction lately.
I have said a few times before that we on this board may be more influential than we realize, and that when we bash the stock, the company, or even each other, it casts a negative light on the investment opportunity for those doing research and thinking about jumping in. How many millions of dollars have we chased away with our bitching and bickering? Who know... Maybe enough to get this thing to the finish line.
We are a relatively small group but we pretty much cover all the related bases, from investment and finance guys to medical device engineering and QA to surgeons, OR personnel, and hospital administration, and device reps. We see and share almost every aspect of what Titan is doing and what they will need to do moving forward. I just hope more potential investors look through the occasional negative post and see that we are really all truly enthusiastic and optimistic about this company.
As for Longtai being happy with their investment, I never had a doubt. Surely they saw SPORT in action in some form before handing over $2M. They knew exactly what they were getting into and that the risk was extremely small at that point.
Message in reply to:
...how "amateur investor message boards offer the best research that can be done" (Hansen CEO Rodney Sacks).
Street Register says they are mentioning Titan for the first time... expect it won't be the last. Wall Street exposure is good!
http://streetregister.com/2017/09/26/titan-medical-inc-com-npv-otcmktstitxf-breaks-new-ground-with-procedures/
And headlines that say Titan exceedds experts' expectations are good too!
http://www.baystreet.ca/usnewsalerts/38403/Titan-Medicals-SPORT-Surgical-System-Exceeds-Experts-Expectations
Just trying to be realistic, and not prophetic (or pathetic) like some of the continued skeptics. As usual, just my opinion:
We will have down days. Last week we ran up some nice increases for a few days in a row, then we backtracked by about a day's worth of gains, maybe just some early profit taking from some shorts, if I had to guess. I expect we will continue to see that cycle repeated, some up days and a few down days sprinkled in whenever the price reaches someone's next trigger point for profits. If I had any concern that Jayhawk could be correct in his dime prediction, it would be due to something drastic like patent concerns, but that seems to be a strong point for Titan so that risk isn't as bad for them as it could be for some other potential competitors.
When we have that occasional down day, most likely the sky isn't falling; it's probably just an opportunity to beef up your position a little more before the next three-day run up. With the attention this stock is getting, I expect to see more shorts jumping in to do their little short-term flipping, so I'm thinking we will see a bumpy ride on a fairly steep overall uphill trajectory, but the each of the bumps shouldn't last too long.
Mostly up, up and up from here!
I would imagine they built in enough time into the schedule to handle a few relatively minor design changes, followed by some regression testing to the design changes. If they come out of this with no real change requests from the surgeons using it in the trials, it could conceivably cut a couple more months off the current schedule (which they are already ahead of due to early delivery to Nicholson).